Recent 8-K filings for PPCB
Highest-materiality recent filing
Nasdaq notifies Propanc Biopharma of non-compliance with $1.00 minimum bid price rule
- Notice received Dec 31, 2025; bid price below $1.00 for 35 consecutive business days.
- Compliance deadline June 30, 2026; must close at $1.00+ for 10 consecutive days.
-
Nasdaq notifies Propanc Biopharma of non-compliance with $1.00 minimum bid price rule
Notice received Dec 31, 2025; bid price below $1.00 for 35 consecutive business days.
-
Propanc Biopharma closes $1.0M private placement of Series C Preferred Stock to Hexstone Capital
Hexstone purchased 100 Series C Preferred shares at $10,000 each plus a warrant for up to 9,900 additional shares; total cash $1,000,099.
-
Propanc Biopharma enters Series C Preferred Stock financing with Hexstone Capital
Issues 100 shares of Series C Preferred convertible at lesser of $5.00 fixed or 85% of lowest trading price over conversion period.
-
Propanc Biopharma prices $4M public offering, uplists to Nasdaq; appoints two independent directors
Raised $4M gross ($3.34M net) via public offering of 1M shares at $4.00/sh; underwriters have 45-day option for 150K more.
-
Principal $67,860 for net $58,000; matures Apr 16, 2026; 15% one-time interest.
-
Propanc Biopharma raises $108K in two convertible note financings in Feb 2025
$65,000 convertible note (purchase price $56,000) issued Feb 6; 15% flat interest, maturity Nov 30, 2025.
-
Propanc Biopharma raises $46,875 via convertible note at 35% discount and 8% interest
Principal amount $50,000; purchase price $46,875; net proceeds for working capital.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.32 · Most common event debt